Watch CNBC's full interview with Pfizer CEO Albert Bourla
Pfizer CEO Albert Bourla sits down with CNBC's Meg Tirrell and the 'Squawk Box' team to discuss the company's plans to develop a new vaccine to target the worrisome omicron coronavirus variant. Bourla also discusses the pharma giant's oral antiviral pill under development, known as Paxlovid. Pfizer now expects to make 80 million treatment courses of the pill, up from a previously estimated 50 million.
Mon, Nov 29 202110:44 AM EST